LMB In The News

RSS feed of lmb-in-the-news posts

Towards preventing neurodegenerative diseases

ALZ_forum_logo

Research led by the LMB’s Anne Bertolotti has discovered a selective inhibitor of a phosphatase enzyme that could prevent protein misfolding diseases. The scientists showed that the new molecule, dubbed Sephin1, countered the effects of aggregating proteins in mouse models of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease, and might do so for other neurodegenerative disorders. More…

Published

Mechanism-based therapeutics of common human neurodegenerative diseases

University Of Cambridge

The LMB and the Department of Clinical Neurosciences have announced an initiative in mechanism-based therapeutics of common human neurodegenerative diseases. This initiative, developed by Michel Goedert and Alastair Compston, aims to identify core mechanisms of protein aggregation and spreading in neurodegeneration, and to apply that knowledge to study putative new therapies. More…

Published

First pictures of the mitoribosome taken

Chemical & Engineering News

Researchers, including a team from the LMB, have obtained structures of complete ribosomes from mammalian mitochondria at near-atomic resolution for the first time. More…

Published

Body clock expert talks to students

IOM_Today

Michael Hastings delivers sixth form lecture at King William’s College, Isle of Man, on his research into circadian rhythms and biological clocks. More…

Published

Image of the Week: Structure of the dynactin complex

Wellcome Trust

The structure of the dynactin complex, solved by Andrew Carter’s group at the LMB, is the cover story on this week’s Science and is the Wellcome Trust’s Image of the week. The picture shows a model of the dynein/dynactin protein machine that moves cargo around the cell, that was determined using electron cryo-microscopy. More…

Published

David Komander part of collaborative consortium in the field of deubiquitinating enzymes.

bwlogo_web

FORMA Therapeutics and Cancer Research Technology, Ltd (CRT) have announced the formation of two new virtual Asset Discovery and Development Companies (ADDCos) to represent the collective efforts of the consortium in the field of deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of academic thought leaders, FORMA drug discovery scientists and a world class development network. More…

Published

Biologist Venki Ramakrishnan to lead Royal Society

BBC News

The next president of the Royal Society will be the Nobel-winning LMB researcher Venki Ramakrishnan. He will succeed Paul Nurse in December 2015. After hearing of the confirmation, Venki told the BBC News that he was “very honoured” to be the society’s president elect. More…

Published

Reaction map suggests meteorite chemistry route to life

chemistry-world-logo_bg

LMB scientists have found a reaction network that they believe shows that ‘pretty much everyone’ working on life’s molecular origins is wrong – but also ‘right, in a sense’. Until now, the field has warred over which biomolecule, emerged first. But John Sutherland’s group found the different types may have appeared simultaneously. More…

Published

In the beginning was the U1A protein: a personal reflection

journal_logo_standalone

LMB’s Kiyoshi Nagai looks back on his research on the spliceosome, RNA-protein interactions and the RNA recognition motif, U1A protein, for RNA journal. More…

Published

British biotech Heptares snapped up by Japan’s Sosei in $400m deal

The Telegraph

The Telegraph reports that the LMB spin-out company Heptares has been acquired by Japanese pharmaceutical company Soseito. The group’s research and development activities and 72 employees will remain in Hertfordshire, and Heptares will operate as an autonomous subsidiary to Sosei. Heptares is developing a string of drugs using a technology which can determine the precise shape of the target molecule, originally developed in the LMB. Its most advanced drug, which aims to treat Alzheimer’s, recently entered human trials. More…

Published